Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 6Multiple Myeloma 5Prostatic Neoplasms 4Neoplasm Metastasis 4Hematologic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Head and Neck Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neurofibromatosis 1 2Neurofibroma, Plexiform 2Neuroendocrine Tumors 2Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma 2von Hippel-Lindau Disease 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × 30 days × Clear all
NCT03765918 2026-05-12

MK-3475-689

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
714 enrolled 90 charts 1 FDA
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡